Abstract
Humoral immunodeficiency is a heterogeneous group of rare disorders. The availability of IVGG has meant significant improvement for many patients, but infections continue to occur even on Ig replacement therapy. This may be partially due to associated T cell defects, the inability of current therapy to provide antibody effectively to mucosal surfaces, or the difficulty of providing antibody of sufficiently high titer, affinity, or specificity during infection. A combination of maintenance Ig replacement coupled with increased amounts of Ig and appropriate antibiotics during specific infections remain the mainstays of current therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.